SCHEMBL5215950

SCHEMBL5215950

O=C(NC1CCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)cc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 13/20 0.56
SELP P16109 3/20 0.42
TYRO3 Q06418 3/20 0.42
CHEK1 O14757 2/20 0.42
IKBKB O14920 2/20 0.42
AURKA O14965 2/20 0.42
MAP4K4 O95819 2/20 0.42
PAK4 O96013 2/20 0.42
CHEK2 O96017 2/20 0.42
ABL1 P00519 2/20 0.42
EGFR P00533 2/20 0.42
INSR P06213 2/20 0.42
LCK P06239 2/20 0.42
FGFR1 P11362 2/20 0.42
CSNK2A2 P19784 2/20 0.42
CCNA2 P20248 2/20 0.42
CDK2 P24941 2/20 0.42
MAPK1 P28482 2/20 0.42
EPHA2 P29317 2/20 0.42
CCND3 P30281 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5214293 0.90 CNR2 (0.70) CNR2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5213113 0.86 CNR2 (0.54) CNR2MAPTHCRTR1
SCHEMBL5214601 0.86 CNR2 (0.55) CNR2MAPTHCRTR1
SCHEMBL5212581 0.84 CNR2 (0.78) CNR2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5216176 0.83 CNR2 (0.72) CNR2MAPK1CYP3A4CYP2D6CYP2C9
SCHEMBL5213951 0.82 CNR2 (0.65) CNR2MAP4K4MAPT
SCHEMBL5215861 0.82 CNR2 (0.81) CNR2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5212098 0.82 CNR2 (0.74) CNR2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5213027 0.81 CNR2 (0.82) CNR2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5214603 0.81 CNR2 (0.62) CNR2EGFRCYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565442-B1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2007-11-14 EP claimed
EP-1565442-B1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2007-11-14 EP disclosed
US-20060240048-A1 Pyridine derivatives as cb2 receptor modulators GLAXO GROUP LIMITED (GB) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060240048-A1 Pyridine derivatives as cb2 receptor modulators CNR2, CNR1, TRPV1 CNR2 1/4885SELP 2902/4885TYRO3 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.